Trez, I absolutely agree there is a real and growing demand for the product. My concern is the disconnect between the stock and the product. Sooner or later it will come in line but the question is when. This thing may very well get bought out in a few years for a few hundred million dollars returning big returns to investors getting in now. BIG ASSUMPTION HERE, as long a Rich can grow the company without diluting the current shareholders this thing could see a buyout at 5 or 10 cents per share down the road. The company has no cash and expansion isn't cheap so it will be interesting to see how Rich navigates those waters. Every share he issues gets multiplied by the Series D preferreds so if the share count skyrockets that 5 or 10 cents per share starts shrinking. I'm excited to watch how this one plays out over the next few years.
I agree with you...I don't know what people think but sales are solid for a brand new product...growth of 20% to 30% quarter to quarter is very good...that puts you near 100% growth quarter over quarter which is significant growth...this product is just starting to gain traction...this will really be rolling by end of 2018...who has the time to wait one more year??? Gonna be a rocky road getting there but this product is doing well for still being less than a year old
Agree, today's 1000 cases in a week NEWS is amazing... Let's review the Sales Targets for Bellissima..
On November 12, 2015, Bellissima Spirits LLC (“Bellissima”) entered into a License Agreement with Christie Brinkley, Inc. (the “Bellissima Licensor”), an entity owned by Christie Brinkley (“Brinkley”), to use Brinkley’s endorsement, signature, and other intellectual property owned by the Bellissima Licensor. Iconic has agreed to guarantee and act as surety for Bellissima’s obligations under certain sections of the License Agreement and to indemnify the Bellissima Licensor and Brinkley against third party claims. Also, Brinkley was granted a 24 month option to purchase 1% of the outstanding shares of Iconic common stock on a fully diluted basis (as of the date of Brinkley’s exercise of the option) at an exercise price of $0.001 per share.
Pursuant to the License Agreement with the Bellissima Licensor (see note 9a. above), Bellissima is obligated to pay the Bellissima Licensor a Royalty Fee equal to 10% of monthly gross sales of Bellissima Brand products payable monthly. The Bellissima Licensor has the right to terminate the endorsement if Bellissima fails to sell 10,000 cases of Bellissima Brand products in year 1, 15,000 cases in year 2, or 20,000 cases in year 3 and each subsequent year.
Market Data 
Markets 
AI
